NanoViricides, Inc. (NASDAQ:NNVC)

BRIEF

published on 05/28/2025 at 12:35, 4 days 13 hours ago

NanoViricides sera présenté à la convention internationale BIO de Boston

NanoViricides Antiviral À Large Spectre Médicament NV-387 Convention BIO 2025 Technologies De Plate-forme
BRIEF

published on 05/28/2025 at 12:35, 4 days 13 hours ago

NanoViricides to Showcase at Boston's BIO International Convention

NanoViricides Broad-spectrum Antiviral NV-387 Drug BIO Convention 2025 Platform Technologies
PRESS RELEASE

published on 05/28/2025 at 12:30, 4 days 13 hours ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
NanoViricides to present at BIO International Convention 2025 on June 16 in Boston, MA, showcasing breakthrough antiviral drug NV-387 with broad-spectrum efficacy and unique mechanism

NanoViricides NV-387 BIO International Convention Antiviral Drug Clinical Stage
BRIEF

published on 05/22/2025 at 12:35, 10 days 13 hours ago

NanoViricides Comments on New FDA COVID Vaccine Policy

FDA NanoViricides Antiviral Drugs COVID Vaccine Policy Public Health Strategy
BRIEF

published on 05/22/2025 at 12:35, 10 days 13 hours ago

NanoViricides commente la nouvelle politique de la FDA concernant les vaccins contre la COVID-19

FDA NanoViricides Médicaments Antiviraux Politique De Vaccination Contre La COVID Stratégie De Santé Publique
PRESS RELEASE

published on 05/22/2025 at 12:30, 10 days 13 hours ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
NanoViricides, Inc. comments on the new COVID Vaccine Booster Shots policy adopted by the US FDA with focus on specific high-risk groups. Dr. Anil Diwan emphasizes evidence-based decision making for vaccine boosters

NanoViricides Inc. COVID Vaccine Booster Shots US FDA Policy Vaccine Effectiveness Dr. Anil Diwan
BRIEF

published on 05/16/2025 at 12:35, 16 days 13 hours ago

NanoViricides Advances Antiviral NV-387 in Phase II Trials

Phase II Trial Financial Update Broad-spectrum Antiviral MPOX Treatment Measles Outbreak
BRIEF

published on 05/16/2025 at 12:35, 16 days 13 hours ago

NanoViricides fait progresser l'antiviral NV-387 dans les essais de phase II

Essai De Phase II Mise À Jour Financière Antiviral À Large Spectre Traitement MPox Épidémie De Rougeole
PRESS RELEASE

published on 05/16/2025 at 12:30, 16 days 13 hours ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NanoViricides, Inc. reports filing Form 10-Q for quarter ending March 31, 2025 with SEC. Clears Phase II trial for NV-387 drug to treat MPox disease & explores Measles and Bird Flu treatments. Company has strong financials

NanoViricides NV-387 Financials Form 10-Q Phase II Trial
BRIEF

published on 05/14/2025 at 12:35, 18 days 13 hours ago

NanoViricides progresse avec le médicament antiviral à large spectre NV-387

Médicaments Antiviraux Traitement MPox Épidémie De Rougeole Développement NV-387 Stratégie Mondiale En Matière De Santé

Published on 06/02/2025 at 01:00, 1 hour 19 minutes ago

Sparta Capital Announces Filing of Interim Financial Statements
Published on 05/31/2025 at 06:16, 1 day 20 hours ago

Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
Published on 05/31/2025 at 03:30, 1 day 22 hours ago

Avant Brands Inc. Announces Voting Results From 2025 Annual General Meeting of Shareholders
Published on 05/31/2025 at 01:45, 2 days ago

GLG Life Tech Corporation Reports 2025 First Quarter Financial Results
Published on 05/30/2025 at 23:10, 2 days 3 hours ago

CORRECTION: Nextech3D.ai Migrates MAP Dynamics to AWS, Enabling Scalable AI Architecture and Accelerated Deployment

View all ACCESSWIRE

Published on 06/01/2025 at 22:26, 3 hours 53 minutes ago

KKR Increases Offer Price for Public Purchase Offer for DATAGROUP Shares conditional upon Final Acceptance Level, Best and Final Offer for DATAGROUP Shares Expires on 6 June 2025
Published on 06/01/2025 at 22:12, 4 hours 7 minutes ago

EQS-Adhoc: DATAGROUP SE: KKR Increases Offer Price for Public Purchase Offer for DATAGROUP Shares conditional upon Final Acceptance Level
Published on 06/01/2025 at 10:00, 16 hours 19 minutes ago

OPPO and the UEFA Champions League Final: Powering Football Innovation On and Off the Pitch
Published on 05/31/2025 at 21:00, 1 day 5 hours ago

Leclanché annonce le dépôt d'une demande de prolongation du délai de publication du rapport annuel 2024 et la suspension temporaire de la cotation de ses actions nominatives à la SIX Swiss Exchange
Published on 05/31/2025 at 21:00, 1 day 5 hours ago

Leclanché SA: Leclanché announces filing of request to extend the publication deadline for the 2024 Annual Report and the temporary suspension of trading of its registered shares on SIX Swiss Exchange

View all EQS

Published on 05/30/2025 at 22:00, 2 days 4 hours ago

Information sur les comptes annuels
Published on 05/30/2025 at 22:00, 2 days 4 hours ago

Information on the Annual Financial Statements
Published on 05/30/2025 at 18:14, 2 days 8 hours ago

Emova Group - Rapport annuel de Durabilité 23/24
Published on 05/28/2025 at 23:00, 4 days 3 hours ago

Standstill Commitments to hold shares of the company
Published on 05/28/2025 at 23:00, 4 days 3 hours ago

Engagements collectifs de conservation de titres de la société

View all LES ECHOS COMFI WIRE

News